Alteon Incorporated

The Rockefeller University

The Picower Institute for Medical Research

Other

Synvista Therapeutics, Inc.

Dilip R Wagle

Peter C Ulrich

Anthony Cerami

John J Egan

Sara Vasan

San-Bao Hwang

Michael E Lankin

Edmond Joseph LaVoie

Stanley Charles Bell

Martin Gall

David H Shih

Sheng Ding Fang

Taikyun Rho

Sheng-Ding Fang

Jack Egan

John Resek

Ihor Terleckyj

Sarah Vasan

Provided is a method of treating or ameliorating or preventing glaucoma, decreasing intraocular pressure or improving or amemliorting ocular accommodation in an animal, including a human comprising administering an intraocular pressure decreasing or accommodation improving amount of a compound of the formula I: 

Method for treating glaucoma IC

Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 

Method for treating fibrotic diseases and other indications

Provided is a method of treating or ameliorating a number of indications in an animal, including a human, comprising administering an effective amount of a compound of the formula I or IA,wherein J is oxygen, sulfur, or N&#x2014;R.

Method for treating fibrotic diseases or other indications utilizing thiazole, oxazole and imidazole compounds

The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain useful agents are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A novel immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.

Preventing and reversing the formation of advance glycosylation endproducts

Provided are, among other things, compounds of formula I or IA,Also provided are methods of treatment with such compounds.

Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging

The present invention relates to compositions and methods for reversing advanced glycosylation end product-mediated cross-linking and protein aging. Accordingly, compositions are described which comprise thiazolium compounds substituted with heterocyclic groups which are capable of reversing the formation of advanced glycosylation end product cross-links. Both industrial and therapeutic applications for the invention are disclosed, as food spoilage and animal protein aging can be treated. Such compounds have particular application in the treatment of protein aging such as is responsible for the complications of aging and diabetes.

Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds

Provided, among other things, is a compound of the formula:

Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging

Method for treating fibrotic diseases or other indications IIC

Glucose and lipid lowering compounds

Synthesis of thiazolium compounds

A method and compositions are disclosed for, among other things, in an animal, (i) improving the elasticity or reducing wrinkles of the skin, treating (ii) diabetes or treating or preventing (iii) adverse sequelae of diabetes, (iv) kidney damage, (v) damage to blood vasculature, (vi) hypertension, (vii) retinopathy, (viii) damage to lens proteins, (ix) cataracts, (x) peripheral neuropathy, or (xi) osteoarthritis.

Thiazolium compounds and treatments of disorders associated with protein aging

The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain agents useful are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.

Method of treating certain indications associated with hyperglycemia

Triazine compounds and method of use therefor

Provided are, among other things, lipid-lowering or glucose-lowering methods and compounds, particularly lipid-lowering or glucose-lowering compounds, with an A-B ring structure as follows:

Growing community of inventors

Valley Cottage, NY, United States of America

Dilip R Wagle